The insurance price of MDS Korea’s immuno-oncology drug Keytruda(pembrolizumab) inj. that is used for non-small-cell lung cancer and Hodgkin lymphoma will drop 25.6% with its reimbursement extended from the second-line to the first-line starting next month,

Astellas Korea’s Xospata 40mg (gilteritinib), as well as Novartis Korea’s Lutathera Inj. that was supplied in Korea as an urgently requested drug will also be individually listed for reimbursement as an expenditure-cap type RSA after reaching an agreement with the National Health Insurance Service.

The Ministry of Health and Welfare announced on the afternoon of the 25th that it had deliberated and passed the ‘amendment to the drug b